NE3107 in Adults With Neurological Symptoms of Long COVID (NCT06847191)
A Double-blind, Randomized Study to Evaluate the Efficacy and Safety of Bezisterim (NE3107) in Adults With Long COVID
🩺 Plain-English Summary (8th-Grade Level)
Long COVID is a condition where debilitating symptoms can persist for months after a COVID-19 infection. This study aims to evaluate the effects of NE3107 on several neurological symptoms reported in people with Long COVID including difficulty concentrating or remembering things ("brain fog") and fatigue. This study is designed as a signal-seeking proof-of-concept Phase 2 study. The primary outcome is intended for estimation and hypothesis generation rather than formal hypothesis testing. No single endpoint is designated as definitive for study success. Researchers will compare NE3107 to a placebo (a look-alike substance that contains no drug) to see if NE3107 works to treat neurocognitive and fatigue symptoms of long COVID. Participants will: * Take NE3107 or a placebo twice daily for 84 days * Visit the clinic 5 times for checkups and tests and have a follow up phone call
Who can join: Review the eligibility criteria below.
Location: Stanford University — Palo Alto, California
Age range: 18 Years to 69 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (20 Sites)
- Stanford University — Palo Alto, California
- UCSF — San Francisco, California
- University of Colorado — Aurora, Colorado
- Yale University — New Haven, Connecticut
- Clinical Trial Site — Jacksonville, Florida
- Centricity Research — Columbus, Georgia
- Illinois Research Network University of Illinois at Chicago — Chicago, Illinois
- Northwestern University — Chicago, Illinois
- University of Iowa — Iowa City, Iowa
- Norton Infectious Disease Institute — Louisville, Kentucky
- Jadestone Clinical Research — Silver Spring, Maryland
- Clinical Trial Site — Farmington Hills, Michigan
- Mayo Clinic — Rochester, Minnesota
- Icahn School of Medicine at Mount Sinai — New York, New York
- University Hospitals Cleveland Medical Center — Cleveland, Ohio
- Zenos Clinical Research — Dallas, Texas
- University of Texas health Science Center at San Antonio — San Antonio, Texas
- Chronicle Bio Inc. — Park City, Utah
- Swedish Center for Research and Innovation — Seattle, Washington
- West Virginia University — Morgantown, West Virginia
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Long COVID
- Ensitrelvir for Viral Persistence and Inflammation in People Experiencing Long COVID — San Francisco, California
- The Long COVID Treatment Trial — La Jolla, California
- tVNS in Long COVID-19 — New York, New York
- Nutritional Management of Post COVID-19 Cognitive Symptoms — Edmonton, Alberta
- Pain in Long COVID-19: the Role of Sleep — Boston, Massachusetts
- Long COVID Immune Profiling — Nashville, Tennessee
Explore by condition: All Long COVID clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.